WO1997048382A3 - Multiple-unit type prolonged action drug preparation - Google Patents

Multiple-unit type prolonged action drug preparation Download PDF

Info

Publication number
WO1997048382A3
WO1997048382A3 PCT/JP1997/001836 JP9701836W WO9748382A3 WO 1997048382 A3 WO1997048382 A3 WO 1997048382A3 JP 9701836 W JP9701836 W JP 9701836W WO 9748382 A3 WO9748382 A3 WO 9748382A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug preparation
unit type
cilostazol
prolonged action
action drug
Prior art date
Application number
PCT/JP1997/001836
Other languages
French (fr)
Other versions
WO1997048382A2 (en
Inventor
Tadashi Mukai
Masami Koike
Toshio Nakamura
Yuzo Kimura
Original Assignee
Otsuka Pharma Co Ltd
Tadashi Mukai
Masami Koike
Toshio Nakamura
Yuzo Kimura
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Tadashi Mukai, Masami Koike, Toshio Nakamura, Yuzo Kimura filed Critical Otsuka Pharma Co Ltd
Priority to AU29768/97A priority Critical patent/AU2976897A/en
Publication of WO1997048382A2 publication Critical patent/WO1997048382A2/en
Publication of WO1997048382A3 publication Critical patent/WO1997048382A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a multiple-unit type prolonged release action drug preparation which is characterized by containing at least 2 small tablets of sustained release type drug preparation obtained by formulating cilostazol with hydroxypropylmethylcellulose as the base material of the drug preparation. By formulating cilostazol as in the form of a multiple-unit type prolonged release action drug preparation of the present invention, side-effects, such as headache and other symptoms caused by high blood concentration of cilostazol due to the rapid absorption, can be reduced.
PCT/JP1997/001836 1996-06-18 1997-05-29 Multiple-unit type prolonged action drug preparation WO1997048382A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU29768/97A AU2976897A (en) 1996-06-18 1997-05-29 Multiple-unit type prolonged action drug preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP15671896 1996-06-18
JP8/156718 1996-06-18

Publications (2)

Publication Number Publication Date
WO1997048382A2 WO1997048382A2 (en) 1997-12-24
WO1997048382A3 true WO1997048382A3 (en) 1998-02-19

Family

ID=15633827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/001836 WO1997048382A2 (en) 1996-06-18 1997-05-29 Multiple-unit type prolonged action drug preparation

Country Status (3)

Country Link
AU (1) AU2976897A (en)
ID (1) ID17125A (en)
WO (1) WO1997048382A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67802C2 (en) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
EG23951A (en) * 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
US20050186276A1 (en) * 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
KR20080076440A (en) * 2007-02-16 2008-08-20 (주)아모레퍼시픽 Controlled release preparation containing cilostazol and process for the preparation thereof
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60228410A (en) * 1984-04-26 1985-11-13 Otsuka Pharmaceut Co Ltd Long-acting drug preparation
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
EP0463173A1 (en) * 1990-01-08 1992-01-02 Otsuka Pharmaceutical Co., Ltd. Hair tonic and dressing composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60228410A (en) * 1984-04-26 1985-11-13 Otsuka Pharmaceut Co Ltd Long-acting drug preparation
US4734285A (en) * 1985-10-28 1988-03-29 The Dow Chemical Company Sustained release compositions
EP0463173A1 (en) * 1990-01-08 1992-01-02 Otsuka Pharmaceutical Co., Ltd. Hair tonic and dressing composition

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9247, Derwent World Patents Index; Class A03, AN 86-003017 *
PATENT ABSTRACTS OF JAPAN vol. 010, no. 098 (C - 339) 15 April 1986 (1986-04-15) *
SUCKER H. ET AL: "Pharmazeutische Technologie", 1991, THIEME VERLAG, STUTTGART, XP002046215, 189560 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8865695B2 (en) 2009-01-08 2014-10-21 Lipocine Inc. Steroidal compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9205057B2 (en) 2010-11-30 2015-12-08 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9480690B2 (en) 2010-11-30 2016-11-01 Lipocine Inc. High-strength testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters

Also Published As

Publication number Publication date
WO1997048382A2 (en) 1997-12-24
AU2976897A (en) 1998-01-07
ID17125A (en) 1997-12-04

Similar Documents

Publication Publication Date Title
EP1283054A4 (en) Drugs for complications of diabetes and neuropathy and utilization thereof
WO1997048382A3 (en) Multiple-unit type prolonged action drug preparation
CA2030838A1 (en) Preparations containing l-carnitine
ZA894728B (en) A new pharmaceutical formulation as well as a process for its preparation
SI0636364T1 (en) Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
WO2004041153A3 (en) Pharmaceutical composition including low dosages of desmopressin
MY129234A (en) Oral pharmaceutical forms of administration with a delayed action with tramadol.
EP0151344A3 (en) A chewing gum composition, a process for preparing a chewing gum tablet therefrom, and a chewing gum tablet
AU764280C (en) Process for the preparation of pellets with a content of up to 90 wt. per cent of a pharmaceutical active ingredient
ES2010226A6 (en) Stable granulocyte colony stimulating factor composition
CA2326761A1 (en) Antitumor agent
IE881916L (en) Press-coated dihydropyridine tablets
ATE311227T1 (en) FAST-ACTING, FREEZE-DRIED, ORAL, PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF MIGRAINE
CA2208047A1 (en) Increasing creatine and glycogen concentration in muscle
DE3766200D1 (en) L-DOPA CONTAINING MEDICINAL PRODUCT.
WO2002004421A3 (en) Pyridoxine and pyridoxal analogues: cardiovascular therapeutics
DE69034226D1 (en) Preparation process of huperzine A and its analogs and compounds useful thereto
CA2117769A1 (en) Liposome composition
CA2290482A1 (en) Fructan containing composition for the prevention and treatment of colon cancer
CA2063273A1 (en) Surfactant compositions and methods
WO2001026621A3 (en) Orally distintegrating composition comprising mirtazapine
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
CA2238278A1 (en) Antigenic protein originating in malassezia
MXPA01007210A (en) Therapeutic agent for parkinson's disease including function improving agent for astrocyte.
IE802033L (en) Dibenzazepine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN KR MX SG US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN KR MX SG US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA